Improving the long-term response to antidepressants by establishing an individualized platform based on variability and chronotherapy.


Journal

International journal of clinical pharmacology and therapeutics
ISSN: 0946-1965
Titre abrégé: Int J Clin Pharmacol Ther
Pays: Germany
ID NLM: 9423309

Informations de publication

Date de publication:
Dec 2021
Historique:
accepted: 15 11 2021
pubmed: 15 10 2021
medline: 18 11 2021
entrez: 14 10 2021
Statut: ppublish

Résumé

Despite the availability of multiple interventions, treatment-resistant depression (TRD) is still a major clinical challenge that has multiple factors associated with its development. Depression is a highly dynamic condition, and both the triggers which underlie its pathogenesis and the loss of response to drugs continuously change. These, along with large interpatient and intrapatient unpredictability, further complicate overcoming decreased response to drugs which may worsen the prognosis in some patients. In this review, we discuss mechanisms associated with loss of response to antidepressants and focus on the potential role of the autonomic nervous system and chronobiology in the pathogenesis of the disease and subsequent response to therapy. We introduce a novel treatment strategy which is based on individualized variability and guided by chronotherapy regimens. We also suggest the implementation of a personalized algorithm which comprises quantifiable signatures associated with the mechanisms of the disease and which underlie the loss of response to drugs. To overcome the deleterious compensatory responses in a highly dynamic system in patients with depression, we propose a closed-loop therapeutic regimen tailored to patients that enables improved responses to current therapies. Implementing guided algorithms tailored to patients are expected to shed light on some of the mechanisms involved in the development of TRD, and will enable the development of new therapeutic strategies for improving the long-term drug response.

Sections du résumé

BACKGROUND BACKGROUND
Despite the availability of multiple interventions, treatment-resistant depression (TRD) is still a major clinical challenge that has multiple factors associated with its development. Depression is a highly dynamic condition, and both the triggers which underlie its pathogenesis and the loss of response to drugs continuously change. These, along with large interpatient and intrapatient unpredictability, further complicate overcoming decreased response to drugs which may worsen the prognosis in some patients.
AIMS OBJECTIVE
In this review, we discuss mechanisms associated with loss of response to antidepressants and focus on the potential role of the autonomic nervous system and chronobiology in the pathogenesis of the disease and subsequent response to therapy.
RESULTS RESULTS
We introduce a novel treatment strategy which is based on individualized variability and guided by chronotherapy regimens. We also suggest the implementation of a personalized algorithm which comprises quantifiable signatures associated with the mechanisms of the disease and which underlie the loss of response to drugs. To overcome the deleterious compensatory responses in a highly dynamic system in patients with depression, we propose a closed-loop therapeutic regimen tailored to patients that enables improved responses to current therapies.
CONCLUSION CONCLUSIONS
Implementing guided algorithms tailored to patients are expected to shed light on some of the mechanisms involved in the development of TRD, and will enable the development of new therapeutic strategies for improving the long-term drug response.

Identifiants

pubmed: 34647865
pii: 188901
doi: 10.5414/CP204000
doi:

Substances chimiques

Antidepressive Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

768-774

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH